| NCT06914609 | REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome | RECRUITING | PHASE3 | 2025-06-10 | 2030-04 | 2027-08 |
| NCT06673069 | Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD) | ACTIVE_NOT_RECRUITING | PHASE1 | 2024-12-20 | 2027-03 | 2027-02 |
| NCT06430385 | ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS) | RECRUITING | PHASE1, PHASE2 | 2024-10-21 | 2030-04 | 2027-09 |
| NCT06150716 | Orbit Study: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered ION356 in Participants With Pelizaeus Merzbacher Disease (PMD) | RECRUITING | PHASE1 | 2024-04-10 | 2028-06 | 2028-06 |
| NCT06153966 | PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717 | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2024-01-04 | 2027-07 | 2025-07 |
| NCT05681351 | CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) | RECRUITING | PHASE3 | 2022-12-13 | 2027-03 | 2027-03 |
| NCT05667493 | An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) | ENROLLING_BY_INVITATION | PHASE3 | 2022-11-30 | 2029-08 | 2029-08 |
| NCT05610280 | A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia | COMPLETED | PHASE3 | 2022-11-21 | 2025-06-09 | 2024-08-08 |
| NCT05579860 | A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants | COMPLETED | PHASE1 | 2022-10-05 | 2023-05-22 | 2023-05-22 |
| NCT05552326 | A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia | COMPLETED | PHASE3 | 2022-08-31 | 2025-09-12 | 2024-12-17 |
| NCT04165486 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON) | RECRUITING | PHASE1 | 2022-07-21 | 2027-09 | 2027-09 |
| NCT05392114 | A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-07-13 | 2027-03 | 2026-12 |
| NCT05355402 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia | COMPLETED | PHASE2 | 2022-05-09 | 2023-12-21 | 2023-03-22 |
| NCT05314439 | A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled Hypertension | COMPLETED | PHASE2 | 2022-04-29 | 2023-02-15 | 2023-01-31 |
| NCT05185843 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-02-25 | 2027-06 | 2027-06 |
| NCT05071300 | A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-01-04 | 2029-08 | 2029-08 |
| NCT05143957 | A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera | ACTIVE_NOT_RECRUITING | PHASE2 | 2021-12-30 | 2026-06 | 2025-06-26 |
| NCT05127226 | HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome | RECRUITING | PHASE1, PHASE2 | 2021-12-22 | 2029-03 | 2029-03 |
| NCT05139810 | OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE) | COMPLETED | PHASE3 | 2021-12-03 | 2023-11-09 | 2023-11-09 |
| NCT05130450 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS) | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-11-18 | 2028-02 | 2028-02 |
| NCT05079919 | A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia | COMPLETED | PHASE3 | 2021-10-25 | 2025-07-08 | 2024-10-22 |
| NCT04932512 | A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224 | COMPLETED | PHASE2 | 2021-06-17 | 2024-02-28 | 2024-01-10 |
| NCT04768972 | FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS) | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-06-14 | 2028-03 | 2026-06 |
| NCT04836182 | A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction | COMPLETED | PHASE2 | 2021-06-08 | 2023-01-11 | 2022-10-19 |
| NCT04849741 | A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD) | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-06-01 | 2029-09 | 2025-09 |
| NCT04714320 | A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure | COMPLETED | PHASE2 | 2021-04-28 | 2022-10-03 | 2022-06-29 |
| NCT04934891 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ION547 | COMPLETED | PHASE1 | 2021-03-24 | 2022-09-14 | 2022-09-14 |
| NCT04731623 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION904 | COMPLETED | PHASE1 | 2021-02-26 | 2021-09-11 | 2021-08-12 |
| NCT04398485 | A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma | COMPLETED | PHASE1 | 2021-01-20 | 2024-09-30 | 2024-09-30 |
| NCT04659096 | A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors | COMPLETED | PHASE1 | 2021-01-05 | 2022-10-19 | 2022-10-19 |
| NCT04522180 | A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly | COMPLETED | PHASE2 | 2021-01-04 | 2023-05-04 | 2022-07-15 |
| NCT04441788 | A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB) | TERMINATED | PHASE2 | 2020-12-22 | 2021-08-09 | 2021-04-27 |
| NCT04568434 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS) | COMPLETED | PHASE3 | 2020-11-18 | 2023-10-17 | 2023-07-14 |
| NCT04059406 | Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) | TERMINATED | PHASE2 | 2020-09-24 | 2023-03-28 | 2023-03-28 |
| NCT04302064 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending and Multiple Doses of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Healthy Japanese Participants | COMPLETED | PHASE1 | 2020-04-23 | 2020-09-10 | 2020-09-10 |
| NCT04307381 | An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema | COMPLETED | PHASE2 | 2020-04-01 | 2025-01-24 | 2025-01-24 |
| NCT04136171 | CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-03-13 | 2026-08 | 2026-04 |
| NCT04030598 | A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema | COMPLETED | PHASE2 | 2020-01-07 | 2021-03-01 | 2021-01-04 |
| NCT04136184 | NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | COMPLETED | PHASE3 | 2019-12-11 | 2023-07-12 | 2023-04-11 |
| NCT04014335 | A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy | COMPLETED | PHASE2 | 2019-12-04 | 2024-04-11 | 2024-02-08 |
| NCT04083222 | A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx | COMPLETED | PHASE2 | 2019-11-13 | 2020-07-20 | 2020-07-20 |
| NCT03976349 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease | COMPLETED | PHASE1 | 2019-08-12 | 2024-08-12 | 2024-08-12 |
| NCT03967249 | Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands | COMPLETED | PHASE2 | 2019-07-25 | 2022-07-07 | 2022-03-31 |
| NCT03815825 | GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) | COMPLETED | PHASE2 | 2019-03-04 | 2024-06-12 | 2024-04-18 |
| NCT03714776 | A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure | COMPLETED | PHASE2 | 2019-01-03 | 2019-11-13 | 2019-11-13 |
| NCT03728634 | Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ). | COMPLETED | PHASE1, PHASE2 | 2018-12-21 | 2020-02-20 | 2020-02-20 |
| NCT03647228 | A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis | COMPLETED | PHASE1 | 2018-12-13 | 2020-10-13 | 2020-10-13 |
| NCT05337878 | A Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pelacarsen (ISIS 681257) in Healthy Japanese Participants | COMPLETED | PHASE1 | 2018-10-15 | 2019-12-18 | 2019-12-18 |
| NCT03548415 | Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands | COMPLETED | PHASE2 | 2018-09-13 | 2021-04-02 | 2021-02-18 |
| NCT03582462 | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of IONIS FXI-LRx in up to 84 Healthy Volunteers | COMPLETED | PHASE1 | 2018-07-09 | 2019-04-26 | 2019-04-26 |
| NCT03446144 | Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) | WITHDRAWN | PHASE2 | 2018-03-16 | 2018-10-10 | 2018-10-10 |
| NCT03358030 | A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis | COMPLETED | PHASE2 | 2017-12-26 | 2019-07-10 | 2019-07-10 |
| NCT03334214 | Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes | COMPLETED | PHASE2 | 2017-11-03 | 2018-11-28 | 2018-11-28 |
| NCT03186989 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease | COMPLETED | PHASE1 | 2017-10-12 | 2022-05-12 | 2022-05-12 |
| NCT03263507 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Donidalorsen (IONIS-PKK-LRx) Administered Subcutaneously to Healthy Volunteers | COMPLETED | PHASE1 | 2017-08-28 | 2018-10-09 | 2018-10-09 |
| NCT03165864 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Healthy Volunteers | COMPLETED | PHASE1 | 2017-05-09 | 2018-09-25 | 2018-09-25 |
| NCT03101878 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx in Healthy Volunteers | COMPLETED | PHASE1 | 2017-04-05 | 2018-08-01 | 2018-03-29 |
| NCT02910635 | A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers | COMPLETED | PHASE1 | 2016-09-19 | 2016-12-20 | 2016-12-20 |
| NCT02900027 | Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides | COMPLETED | PHASE1 | 2016-09 | 2018-04-30 | 2018-04-30 |
| NCT02824003 | Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes | COMPLETED | PHASE2 | 2016-04 | 2017-05-22 | 2016-12-15 |
| NCT02709850 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia | COMPLETED | PHASE1 | 2015-11-30 | 2017-06-26 | 2017-04-12 |
| NCT02553889 | A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis | COMPLETED | PHASE2 | 2015-10 | 2016-11 | 2016-11 |
| NCT02583919 | Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes | COMPLETED | PHASE2 | 2015-09 | 2017-05-11 | 2016-12-15 |
| NCT02519036 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease | COMPLETED | PHASE1, PHASE2 | 2015-08-06 | 2017-11-08 | 2017-11-08 |
| NCT02476019 | A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients | COMPLETED | PHASE2 | 2015-06 | 2016-09 | 2016-07 |
| NCT02414594 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a) | COMPLETED | PHASE1 | 2015-04 | 2016-02 | 2016-02 |
| NCT02300233 | The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia | COMPLETED | PHASE3 | 2015-02-05 | 2017-01-24 | 2016-07-27 |
| NCT02312011 | A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1 | COMPLETED | PHASE1, PHASE2 | 2014-12 | 2016-08 | 2016-07 |
| NCT02211209 | The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome | COMPLETED | PHASE3 | 2014-12 | 2017-03-28 | 2016-12-19 |
| NCT02175004 | Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP) | COMPLETED | PHASE3 | 2014-06-26 | 2021-01-07 | 2020-09-11 |
| NCT02160899 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a) | COMPLETED | PHASE2 | 2014-06 | 2015-11 | 2015-11 |
| NCT01968265 | Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes | COMPLETED | PHASE2 | 2013-10 | 2015-05 | 2015-01 |
| NCT01918865 | Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes | COMPLETED | PHASE2 | 2013-08 | 2015-02 | 2014-10 |
| NCT01885260 | Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes | COMPLETED | PHASE2 | 2013-07 | 2014-11 | 2014-05 |
| NCT01737398 | Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy | COMPLETED | PHASE2, PHASE3 | 2013-03-15 | 2017-11-07 | 2017-03-03 |
| NCT01710852 | Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial Fibrillation | COMPLETED | PHASE2 | 2012-10 | 2014-04 | 2014-04 |
| NCT01713361 | Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty | COMPLETED | PHASE2 | 2012-10 | 2014-08 | 2014-05 |
| NCT01647308 | Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes | TERMINATED | PHASE2 | 2012-07 | 2014-03 | 2014-01 |
| NCT01563302 | Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers | COMPLETED | PHASE1, PHASE2 | 2012-02-27 | 2016-03-23 | 2016-03-23 |
| NCT01529424 | Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia | COMPLETED | PHASE2 | 2012-02 | 2014-01 | 2014-01 |
| NCT01414101 | Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis | COMPLETED | PHASE2 | 2011-08 | 2013-05 | 2013-05 |
| NCT01234025 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC) | COMPLETED | PHASE1, PHASE2 | 2010-11 | 2013-12 | 2013-05 |
| NCT01234038 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel | COMPLETED | PHASE1, PHASE2 | 2010-11 | 2013-01 | 2012-10 |
| NCT01041222 | Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations | COMPLETED | PHASE1 | 2010-01 | 2012-01 | 2011-12 |
| NCT00836225 | Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers | COMPLETED | PHASE1 | 2009-01 | 2012-01 | 2011-10 |
| NCT00734240 | Safety and Tolerability of Single and Multiple Doses of ISIS 353512 in Healthy Volunteers | COMPLETED | PHASE1 | 2008-07 | 2010-03 | 2010-02 |
| NCT00519727 | Safety Study of ISIS 325568 in Healthy Volunteers | COMPLETED | PHASE1 | 2007-08 | 2008-06 | 2008-04 |
| NCT00455598 | Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea | COMPLETED | PHASE2 | 2007-02 | 2009-05 | 2009-03 |
| NCT00365781 | Examination of Dermatologic Effects From Subcutaneous Injections of ISIS 113715 | COMPLETED | PHASE1 | 2006-08 | 2006-09 | |
| NCT00327626 | Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea | WITHDRAWN | PHASE2 | 2006-05-01 | 2007-03-01 | 2007-02-01 |
| NCT00330200 | Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics | TERMINATED | PHASE2 | 2005-11-01 | 2007-03-01 | 2007-03-01 |
| NCT00062816 | Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs | COMPLETED | PHASE1, PHASE2 | 2003-06 | 2004-01 | 2004-01 |
| NCT00063830 | ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis. | COMPLETED | PHASE2 | 2003-04-03 | 2004-10-11 | 2004-10-11 |
| NCT00330330 | Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment | COMPLETED | PHASE2 | 2003-02 | 2006-08 | |
| NCT00063414 | ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis | COMPLETED | PHASE2 | 2002-11-20 | 2005-03-24 | 2005-03-24 |
| NCT00048295 | Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease | COMPLETED | PHASE3 | 2002-05 | | |
| NCT00048321 | ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis | COMPLETED | PHASE2 | 2002-01-01 | 2003-02-01 | 2003-02-01 |
| NCT00035945 | ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections | COMPLETED | PHASE2 | 2001-10-01 | 2004-05-01 | 2004-05-01 |
| NCT00048113 | Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease | COMPLETED | PHASE3 | 2001-01-10 | 2002-04-27 | 2002-04-27 |
| NCT00017407 | Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer | COMPLETED | PHASE3 | 2000-10-13 | 2002-09-09 | 2002-09-09 |
| NCT00002356 | The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes | COMPLETED | PHASE2 | | | |
| NCT00002156 | A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR ) | COMPLETED | PHASE2 | | | |
| NCT00002187 | A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis | COMPLETED | NA | | | |
| NCT00002355 | A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes | COMPLETED | NA | | | |